Skip to content
drillr.ai
Sign up

AMGN

AMGEN INC

NASDAQ · Healthcare · Drug Manufacturers - General · US

$424.94
−1.75%
Ask drillr

  • Oct 15, 2026, 22:51 UTC

    AMGEN INC shares closed at $434.03, up 1.86% from the previous close.

    Source:

  • Oct 7, 2026, 23:01 UTC

    AMGEN INC shares rose 2.6% to $413.08 during the recent trading day.

    Source:

  • Oct 7, 2026, 06:45 UTC

    SPJIMR reported that all 365 participants in its Class of 2028 secured summer internships, with a median monthly stipend of ₹2 lakhs, an average of ₹1.86 lakhs and a highest stipend of ₹3 lakhs.

    Source:

  • Oct 4, 2026, 15:30 UTC

    Oxford Science Enterprises appointed Dr Jeffrey Moore as senior partner and head of life sciences, succeeding Katya Smirnyagina, who will remain as an advisor.

    Source:

  • Oct 2, 2026, 21:45 UTC

    Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, expected to create about 600 jobs with the first module operational in 2031.

    Source:

  • Oct 1, 2026, 22:51 UTC

    Amgen (AMGN) shares closed at $407.27, down 3.38% from the prior trading session.

    Source:

  • Sep 28, 2026, 08:25 UTC

    Keystone announced it is establishing Keystone India with Bengaluru as its first hub and plans to hire talent and expand its workforce in India over the next two years.

    Source:

  • Sep 22, 2026, 23:46 UTC

    Micron Technology shares rose 5% in Tuesday's session to close at $1,096.16, marking a fourth consecutive day of gains and breaking above the $1,042.40 early-entry buy point set on September 9.

    Source:

  • Sep 22, 2026, 13:00 UTC

    Amgen announced positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren's disease.

    Source:

  • Sep 15, 2026, 14:56 UTC

    Amgen plans to implement Veeva Vault CRM globally, consolidating its collaboration with Veeva Systems.

    Source:

  • Sep 8, 2026, 13:15 UTC

    AstraZeneca announced on Tuesday that its cancer drug Imfinzi combined with Amgen's Imdelltra significantly improved overall survival in a late-stage trial for first-line extensive-stage small cell lung cancer.

    Source:

  • Aug 31, 2026, 07:15 UTC

    Amgen announced on Monday that its cholesterol drug Repatha reduced the risk of death by 20% in a study of over 12,000 high-risk patients.

    Source:

  • Aug 27, 2026, 06:00 UTC

    Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.

    Source:

  • Aug 23, 2026, 08:00 UTC

    Beutel Goodman & Co Ltd. reduced its stake in Amgen Inc. by 19.8% during the second quarter of 2026, selling 128,742 shares, according to a Form 13F filing.

    Source:

  • Aug 21, 2026, 08:51 UTC

    Bank of New York Mellon Corp reduced its stake in Amgen Inc. by 2.6% during the quarter, selling 97,857 shares, according to a recent SEC filing.

    Source:

  • Aug 20, 2026, 08:43 UTC

    Aegis Wealth Management LLC acquired a new stake in Amgen Inc., purchasing 2,162 shares valued at approximately $783,000, as disclosed in a recent SEC filing.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 11, 2026, 11:24 UTC

    Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.

    Source:

  • Aug 11, 2026, 08:31 UTC

    BeiGene and Amgen's jointly developed drug Tarlatamab (AnTaid) officially entered clinical use in China, with prescriptions issued at 29 hospitals across 17 cities as of August 10, and supply started on August 7 covering 80 cities and over 200 medical institutions.

    Source:

  • Aug 4, 2026, 20:14 UTC

    Amgen announced it is ending early development of its phase 1 obesity treatment.

    Source:

  • Aug 4, 2026, 20:11 UTC

    Amgen reported its Q2 2026 results on August 4, 2026, with revenue up 9.5% year-over-year to $10 billion, operating income up 32.3% to $3.514 billion, and diluted EPS of $4.37.

    Source:

  • Jul 31, 2026, 20:12 UTC

    Amgen disclosed that some data, including proprietary data, patient protected health information, and other information, had been stolen.

    Source:

  • Jul 30, 2026, 20:01 UTC

    Amgen's Board of Directors declared a $2.52 per share dividend for the third quarter of 2026.

    Source:
Page 1Next →